Navamedic ASA
Astrid T. Bratvedt is a seasoned pharmaceutical executive with extensive experience in research and development, regulatory affairs, and leadership roles. Currently serving as Chief Scientific Officer at Navamedic ASA since January 2019, Astrid previously held the position of Vice President R&D at Novicus Pharma AS, which was acquired by Navamedic in February 2019. Prior to that, Astrid spent nearly three decades at Weifa AS, where roles included Chief Scientific Officer, Vice President of Research and Development, and Vice President of New Products. Astrid's early career included positions at Nycomed Pharma as a Scientific Officer in Biopharmacy. Educational qualifications include a Master's degree in Pharmacy from the University of Oslo, complemented by further studies at Østfold University College and BI Norwegian Business School.
This person is not in any teams
Navamedic ASA
Navamedic is a reliable supplier of high-quality products, delivered to hospitals and through pharmacies, meeting the specific medical needs of patients and consumers. Our product portfolio consists of prescription and OTC pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. Navamedic is present in all Nordic countries, the Baltics and Benelux and has sales of specific products even in other European countries like UK and Greece. Our headquarter is in Oslo, Norway and we are listed on the Oslo Stock Exchange (ticker: NAVA). We are about 30 highly qualified employees with strong competence in regulatory affairs, quality assurance, reimbursement, marketing and sales and thus a full-service provider securing market access through our local competence.